Safety Evaluation of a Potential Anti-Rheumatoid Arthritis Candidate, Levamisole
Jun-Xiang Wang,Jia-Hui Zhang,Mu Guo,Wei-Rui Huang,Han-Lu Zheng,Yi-Qi Liao,Ying-Xue Yan,Zhao-Long Lin,Neng-Fu Qiu,Cui-Ting Dai,Xiang-Bin Yu,Yue Yu
DOI: https://doi.org/10.2147/jir.s477013
IF: 4.5
2024-10-29
Journal of Inflammation Research
Abstract:Jun-Xiang Wang, 1, &ast Jia-Hui Zhang, 1, &ast Mu Guo, 1, &ast Wei-Rui Huang, 1 Han-Lu Zheng, 1 Yi-Qi Liao, 1 Ying-Xue Yan, 1 Zhao-Long Lin, 1 Neng-Fu Qiu, 1 Cui-Ting Dai, 2 Xiang-Bin Yu, 1 Yue Yu 1 1 School of Pharmacy & Fujian Center for New Drug Safety Evaluation, Fujian Medical University, Fuzhou, 350122, People's Republic of China; 2 Department of Pathology, The People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine, Fuzhou, 350004, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yue Yu; Xiang-Bin Yu, Email ; Introduction: Given the limitations and adverse effects of current rheumatoid arthritis (RA) treatments, there is an urgent need for safer and more effective therapeutic options. Levamisole (LVM) is a non-specific immunomodulator with potential for treating skin diseases, tumors, and autoimmune disorders. Recognizing LVM's potential despite its controversial reputation, this study aimed to investigate its safety profile and therapeutic efficacy towards RA. Methods: To evaluate the potential toxicity of LVM, a 28-day oral administration was conducted in SD rats, assessing general toxicity and neurotoxicity using serum biochemical indicators, the Morris water maze test, transmission electron microscopy, and H&E staining. Subsequently, the therapeutic effects of LVM on RA were evaluated. Results: The results showed that 30 mg/kg LVM has promising therapeutic effects in the treatment of RA with negligible toxicity from 45 mg/kg to 180 mg/kg. Discussions: This study provides valuable preclinical data on the safety and efficacy of LVM, laying the groundwork for future clinical applications and potentially offering a safer and more effective treatment option for RA patients. Keywords: levamisole, general toxicity, neurotoxicity, rheumatoid arthritis Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovial inflammation, ultimately leading to erosive damage to cartilage and bone, resulting in joint stiffness and deformity. 1 It is estimated that approximately 0.46% of the global population suffers from RA. 2 Current treatment options for RA include non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, and methotrexate. 3 However, NSAIDs can lead to serious adverse effects, such as gastrointestinal bleeding, renal failure, and heart failure. 4 Glucocorticoids are suitable only for short-term use, as prolonged administration can induce muscle weakness, diabetes, and osteoporosis. 5 While methotrexate is a first-line clinical treatment for RA, its use is also associated with severe adverse reactions. 6 Therefore, it is crucial to develop an effective and safe pharmaceutical agent for the treatment of RA. Levamisole (LVM), a synthetic thiazole derivative, was initially employed as an efficacious broad-spectrum antihelminthic agent. 7,8 Further research has revealed that LVM possesses notable anti-inflammatory and immunomodulatory properties. 9,10 It can induce a type I immune response and stimulate cellular immune responses. Based on its immunomodulatory properties, LVM has been employed in the treatment of a range of conditions, including autoimmune disorders, nephrotic syndrome, infectious diseases, and cancer. 11,12 Additionally, clinical case reports have documented the effective treatment of arthritis with LVM. 13 In a four-month double-blind trial, 40 patients with rheumatoid arthritis received LVM treatment. Of these patients, 50% demonstrated favorable or excellent clinical outcomes. 14 To further elucidate the therapeutic potential of LVM in the management of RA, a comprehensive assessment of its effects in a relevant animal model is warranted. At the same time, it also provides a reference dose for exploring the mechanism of LVM therapy for RA in the future. In the clinical setting, the incidence of adverse events associated with LVM at therapeutic doses is relatively low, with occasional mild side effects such as dizziness, nausea, vomiting, abdominal pain, anorexia, fever, somnolence, and fatigue. Some studies have reported that LVM can cause demyelinating brain lesions, but these usually resolve after discontinuation of the drug. 15 Despite these clinical observations, the limited comprehensive safety data hinders an accurate assessment of the clinical safety of LVM. To ensure that LVM are safe for clinical use, it is necessary to reassess the safety of oral LVMs in relevant -Abstract Truncated-
immunology